Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 61.84 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 85.83 | Oscillator | Sell |
| Williams %R (14) | -1.57 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.06 (Hist 0.06) | Oscillator | Strong Buy |
| Average Directional Index (14) | 13.62 (+DI 28.5 / -DI 18.0) | Trend | Neutral |
Current price $12.93
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 5, 26 |
| EMA 20 | 12.30 | MA | Strong Buy |
| SMA 20 | 12.18 | MA | Strong Buy |
| EMA 50 | 12.06 | MA | Strong Buy |
| SMA 50 | 12.41 | MA | Strong Buy |
| SMA 200 | 9.19 | MA | Strong Buy |
| Keybanc |
| maintain |
| Overweight |
| Overweight |
| Sep 10, 26 | Barclays | maintain | Overweight | Overweight |
| Sep 9, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Aug 19, 26 | BTIG | maintain | Buy | Buy |
| Aug 14, 26 | JP Morgan | maintain | Neutral | Neutral |
| Aug 7, 26 | BTIG | maintain | Buy | Buy |
| Jul 24, 26 | BTIG | maintain | Buy | Buy |
| Jul 21, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Jul 14, 26 | Barclays | maintain | Overweight | Overweight |
TTM vs. 5-year historical average (annual ratios)
| Metric | LFST | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 99.3x | 30.6x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 80.5x | EPS est. 0.16 | Discount |
| Price / Book | 3.4x | 1.8x | Elevated |
| Price / Sales | 3.1x | 2.7x | In line |
| EV / EBITDA | 37.3x | 10.6x | Elevated |
| Return on equity | 3.4% | — | Weak |
| Gross margin | 33.6% | 30.2% | In line |
| Debt / Equity | 0.14 | 0.25 | Conservative |
| Piotroski / Altman Z | 8/9 | Z 4.61 | Safe zone |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 16, 2026 | 2026-10-16 17:26:18 | View |
| SC 13G/A | Oct 5, 2026 | 2026-10-05 11:58:08 | View |
| 4 | Sep 24, 2026 | 2026-09-24 16:24:10 | View |
| 4 | Sep 15, 2026 | 2026-09-15 16:16:04 | View |
| 8-K | Sep 11, 2026 | 2026-09-11 16:24:09 | View |
| 424B7 | Sep 10, 2026 | 2026-09-10 08:14:32 | View |
| 424B7 | Sep 9, 2026 | 2026-09-09 07:35:28 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:52:26 | View |
| 4 | Sep 4, 2026 | 2026-09-04 16:51:58 | View |
| 4 | Aug 26, 2026 | 2026-08-26 17:17:05 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 22, 26 | Bourdon David | director, officer: Chief Executive Officer | G-Gift | 150,000 | — |
| Sep 22, 26 | Bourdon David | director, officer: Chief Executive Officer | G-Gift | 150,000 | — |
| Sep 22, 26 | Bourdon David | director, officer: Chief Executive Officer | G-Gift | 150,000 | — |
| Sep 11, 26 | Tpg Gp A, Llc | 10 percent owner | S-Sale | 18,409,705 @ $12.29 | $226.3M |
| Sep 2, 26 | Bourdon David | director, officer: Chief Executive Officer | J-Other | 150,000 | — |
| Sep 2, 26 | Paunovich Vukasin | officer: Chief Technology Officer | S-Sale | 42,067 @ $12.87 | $541.4K |
| Aug 24, 26 | Varanakis Ann | officer: Chief People Officer | F-InKind | 8,156 @ $12.16 | $99.18K |
| Aug 14, 26 | Deluca Teresa | director | S-Sale | 7,500 @ $12.68 | $95.10K |
Stock news · updated daily
SCOTTSDALE, Ariz., Oct. 15, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental healthcare, will issue its third quarter 2026 earnings release before the market opens on Thursday, November 5, 2026.
HF Sinclair, Accenture and FirstCash post impressive gains as Zacks research portfolios highlight standout performers amid market uncertainty and shifting investor sentiment.
Nearly 3 in 4 Gen Zers Say Fear of an Unwanted Viral Moment Affects Their Mental Health, Self-Expression and Social Participation SCOTTSDALE, Ariz., Sept. 30, 2026 /PRNewswire/ -- A LifeStance Health survey released today finds that the possibility of spontaneous, authentic moments going viral on social media is affecting people's mental well-being and reshaping behavior, self-expression and participation in everyday life.
Vukasin Paunovich disposed of 42,067 shares. The transaction involved shares equal to 17% of the total stake held by the executive prior to the filing.
HighTower Advisors LLC acquired a new position in LifeStance Health Group, Inc. (NASDAQ: LFST) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 74,169 shares of the company's stock, valued at approximately $794,000. Several other large investors have
LifeStance Health Group, Inc. (LFST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
LifeStance Health Group (NASDAQ: LFST - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings. Insider and Institutional Ownership 85.5% of LifeStance Health
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | 0.03 | 0.06 | Beat 83.2% | $435.4M |
| May 7, 2026 | 0.01 | 0.04 | Beat 300.0% | $403.5M |
| Feb 25, 2026 | -0.00 | 0.03 | Beat 3291.5% | $382.2M |
| Nov 6, 2025 | -0.01 | 0.00 | Beat 127.7% | $363.8M |
| Aug 7, 2025 | -0.03 | -0.01 | Beat 66.7% | $345.3M |
| May 7, 2025 | -0.04 | 0.00 | Beat 104.6% | $333.0M |